FBXO32 and Duchenne muscular dystrophy: While our results suggest that atrogin-1 may be manipulated for therapeutic gain in DMD, we wanted to examine whether manipulating levels of BiP, which is regulated by atrogin-1, could provide a possible alternative therapeutic strategy to combat DMD.